Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    July 2022
  1. SHEN Z, Gu L, Liu Y, Wang L, et al
    PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA.
    Oncogene. 2022 Jul 22. pii: 10.1038/s41388-022-02411.
    PubMed     Abstract available


    June 2022
  2. HUANG C, Lv X, Chen P, Liu J, et al
    Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02390.
    PubMed     Abstract available


  3. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    Correction to: An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02356.
    PubMed    


    May 2022
  4. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 May 30. pii: 10.1038/s41388-022-02354.
    PubMed    


    April 2022
  5. ZHU S, Zhang C, Cao D, Bai J, et al
    Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02277.
    PubMed     Abstract available


  6. KOMATSU M, Nakamura K, Takeda T, Chiwaki F, et al
    Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.
    Oncogene. 2022;41:2326-2339.
    PubMed     Abstract available


    March 2022
  7. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 Mar 18. pii: 10.1038/s41388-022-02251.
    PubMed     Abstract available


    February 2022
  8. YOSHIDA A, Phillips-Mason P, Tarallo V, Avril S, et al
    Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
    Oncogene. 2022 Feb 24. pii: 10.1038/s41388-022-02243.
    PubMed     Abstract available


  9. KWON J, Choi H, Ware AD, Morillo BC, et al
    USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02224.
    PubMed     Abstract available


  10. LIAO Y, Huang J, Liu P, Zhang C, et al
    Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer.
    Oncogene. 2022 Feb 12. pii: 10.1038/s41388-022-02202.
    PubMed     Abstract available


  11. MOTA A, Oltra SS, Selenica P, Moiola CP, et al
    Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02221.
    PubMed     Abstract available


  12. LIN L, Shi K, Zhou S, Cai MC, et al
    SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02210.
    PubMed     Abstract available


    January 2022
  13. LI J, Zheng C, Wang M, Umano AD, et al
    ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02149.
    PubMed     Abstract available


  14. JAMES NE, Woodman M, Ribeiro JR
    Prognostic immunologic signatures in epithelial ovarian cancer.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-022-02181.
    PubMed     Abstract available


  15. KAN T, Zhang S, Zhou S, Zhang Y, et al
    Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02139.
    PubMed     Abstract available


    November 2021
  16. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    PubMed     Abstract available


  17. BOUDHRAA Z, Zaoui K, Fleury H, Cahuzac M, et al
    NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02082.
    PubMed     Abstract available


    September 2021
  18. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2021 Sep 23. pii: 10.1038/s41388-021-02020.
    PubMed     Abstract available


  19. FENG Q, Li S, Ma HM, Yang WT, et al
    LGR6 activates the Wnt/beta-catenin signaling pathway and forms a beta-catenin/TCF7L2/LGR6 feedback loop in LGR6(high) cervical cancer stem cells.
    Oncogene. 2021 Sep 6. pii: 10.1038/s41388-021-02002.
    PubMed     Abstract available


    August 2021
  20. LI H, Qi Z, Niu Y, Yang Y, et al
    FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer.
    Oncogene. 2021 Aug 6. pii: 10.1038/s41388-021-01957.
    PubMed     Abstract available


    July 2021
  21. FARES B, Berger L, Bangiev-Girsh E, Kakun RR, et al
    PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.
    Oncogene. 2021 Jul 9. pii: 10.1038/s41388-021-01925.
    PubMed     Abstract available


  22. LI Y, Fei H, Lin Q, Liang F, et al
    ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Oncogene. 2021 Jul 1. pii: 10.1038/s41388-021-01913.
    PubMed     Abstract available


    June 2021
  23. ZHANG J, Guan W, Xu X, Wang F, et al
    A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01891.
    PubMed     Abstract available


  24. WU Y, Guo Q, Ju X, Hu Z, et al
    HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
    Oncogene. 2021 Jun 19. pii: 10.1038/s41388-021-01884.
    PubMed     Abstract available


  25. WU YH, Huang YF, Chang TH, Chen CC, et al
    COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta3 through the NF-kappaB/IGFBP2 axis in ovarian cancer cells.
    Oncogene. 2021 Jun 11. pii: 10.1038/s41388-021-01865.
    PubMed     Abstract available


    May 2021
  26. TAN J, Zheng X, Li M, Ye F, et al
    C/EBPbeta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Oncogene. 2021 May 8. pii: 10.1038/s41388-021-01788.
    PubMed     Abstract available


  27. KUMAGAI K, Takanashi M, Ohno SI, Harada Y, et al
    WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7.
    Oncogene. 2021;40:3695-3706.
    PubMed     Abstract available


    April 2021
  28. LINDZEN M, Ghosh S, Noronha A, Drago D, et al
    Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
    Oncogene. 2021 Apr 30. pii: 10.1038/s41388-021-01784.
    PubMed     Abstract available


  29. YANG WT, Chen M, Xu R, Zheng PS, et al
    PRDM4 inhibits cell proliferation and tumorigenesis by inactivating the PI3K/AKT signaling pathway through targeting of PTEN in cervical carcinoma.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01765.
    PubMed     Abstract available


    March 2021
  30. NI M, Li J, Zhao H, Xu F, et al
    BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
    Oncogene. 2021 Mar 12. pii: 10.1038/s41388-021-01735.
    PubMed     Abstract available


  31. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01710.
    PubMed     Abstract available


    February 2021
  32. MORGAN EL, Patterson MR, Barba-Moreno D, Scarth JA, et al
    The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01679.
    PubMed     Abstract available


  33. XING Y, Chen L, Gu H, Yang C, et al
    Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation.
    Oncogene. 2021 Feb 22. pii: 10.1038/s41388-021-01693.
    PubMed     Abstract available


    January 2021
  34. XIAO Y, Jin L, Deng C, Guan Y, et al
    Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01621.
    PubMed     Abstract available


  35. YOSHIDA K, Yokoi A, Sugiyama M, Oda S, et al
    Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01595.
    PubMed     Abstract available


  36. NOH K, Bach DH, Choi HJ, Kim MS, et al
    The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
    Oncogene. 2021;40:384-395.
    PubMed     Abstract available


    November 2020
  37. SONG Y, Wang M, Tong H, Tan Y, et al
    Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression.
    Oncogene. 2020 Nov 18. pii: 10.1038/s41388-020-01555.
    PubMed     Abstract available


    October 2020
  38. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    PubMed     Abstract available


  39. RANZUGLIA V, Lorenzon I, Pellarin I, Sonego M, et al
    Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Oncogene. 2020;39:6370-6386.
    PubMed     Abstract available


  40. REN S, Gaykalova DA, Guo T, Favorov AV, et al
    HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.
    Oncogene. 2020;39:6327-6339.
    PubMed     Abstract available


    September 2020
  41. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    PubMed     Abstract available


    May 2020
  42. LI J, Alvero AB, Nuti S, Tedja R, et al
    CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
    Oncogene. 2020;39:3965-3979.
    PubMed     Abstract available


    March 2020
  43. HAYASHI T, Sano K, Aburatani H, Yaegashi N, et al
    Initialization of epithelial cells by tumor cells in a metastatic microenvironment.
    Oncogene. 2020;39:2638-2640.
    PubMed    


    January 2020
  44. ZHOU Y, Liu H, Wang J, Wang X, et al
    DeltaNp63alpha exerts antitumor functions in cervical squamous cell carcinoma.
    Oncogene. 2020;39:905-921.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: